Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.


Advances in In Vivo CAR T-cell Therapies

In vivo CAR-T gene therapies could resolve challenges faced by autologous and allogeneic treatments.

Technology for In Vivo CAR T-cell Therapy Advances

Feliza Mirasol is the science editor for 

Although well known in R&D, PK/PD studies are an equally powerful tool for promoting successful biologic drug development.

The Power of PK/PD in mAb Development

Meg Rivers is the former senior editor for 

Experts discuss factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy. 

ADME Studies: Determining Promising Drug Compounds 

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

Chris Spivey is the editorial director of 

Podcasts

How Pfizer’s external-facing research and development scientists uncover the most promising emerging therapy concepts and ideas in the pharmaceutical landscape. 

Drug Solutions Podcast: How Pfizer Views Partnering and Investing for Emerging Therapies

Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.

Precision BioSciences Releases Data on CAR T Therapy Candidates

Collecting relevant data, planning ahead, and communicating with regulatory bodies in pre-IND meeting programs can help companies to avoid roadblocks in IND applications. 

Early Development Challenges in IND Applications

In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology’s science editor, discusses technologies enabling biologics and emerging therapies manufacturing and development with Barry Holtz, PhD, chief scientific officer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies.



Drug Solutions Podcast: Biologic Drug Development and Manufacturing

In this episode of the Drug Solutions Podcast, Meg Rivers, senior editor, interviews Joy Aho, senior product manager at Be The Match BioTherapies, about sourcing autologous and allogeneic cell therapies.

Early Phase Development